Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-15
2005-11-15
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255060, C544S405000, C544S406000, C544S407000, C544S408000, C544S409000, C206S828000
Reexamination Certificate
active
06964965
ABSTRACT:
The present invention provides substituted pyrazine derivatives of Formula I,that are CRF1receptor antagonists, including human CRF1receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.
REFERENCES:
patent: 5795905 (1998-08-01), McCarthy et al.
patent: 5872136 (1999-02-01), Anthony et al.
patent: 5880140 (1999-03-01), Anthony
patent: 5883105 (1999-03-01), Anthony
patent: 6043260 (2000-03-01), Chen
patent: 6399315 (2002-06-01), Perrin et al.
patent: 1097709 (2000-10-01), None
patent: WO 96/39374 (1996-12-01), None
patent: WO 97/36886 (1997-10-01), None
patent: WO 97/36898 (1997-10-01), None
patent: WO 98/27042 (1997-12-01), None
patent: WO 98/27179 (1997-12-01), None
patent: WO 98/29119 (1997-12-01), None
patent: WO 98/27045 (1998-06-01), None
patent: WO 98/38174 (1998-09-01), None
patent: WO 00/59902 (2000-10-01), None
patent: WO 01/55115 (2001-08-01), None
patent: WO 01/60806 (2001-08-01), None
patent: WO 02/19975 (2002-03-01), None
patent: WO 02/100838 (2002-12-01), None
Kehne and De Lombert, “Non-Peptidic CRF1 Receptor Antagonists for the Treatment of Anxiety, Depression and Stress Disorders” Current Drug Targets, vol. 1(5), pp. 467-493 (2002).
Dautzenberg and Hauger, “The CRF peptide family and their receptors: yet more partners discovered” Trends in Pharmacological Sciences, vol. 23(2), pp. 71-77 (Feb. 2002).
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Arato M. et al., Biol. Psychiatry, 1989, 25:355.
Banki C. M. et al., Am. J. Psychiatry, 1987, 144:873.
Berridge, C. W. and A. J. Dunn, Regul. Peptides, 1986, 16:83.
Berridge, C. W. and A. J. Dunn, Horm. Behav., 1987, 21:393.
Berridge, C. W. and A. J. Dunn, Brain Research Reviews, 1990, 15:71.
Blalock, Physiological Reviews, 1989, 69:1.
Britton, K. T. , et al., Pyschopharmacology, 1985, 86:170.
Britton, K. T. , Psychopharmacology, 1988, 94:306.
De Souze, E.B., Hosp. Practice, 1988, 23:59.
De Souza, E. B. et al., J. Neurosci., 1985, 5:3189.
France et al., Biol. Psychiatry, 1988, 28:86.
Gabry, K. E. , Molecular Psychiatry 2000, 7(5), 474-483.
Gold, P. W. et al., Am. J. Psychiatry, 1984, 141:619.
Gold, P. W. et al., New Engl. J. Med., 1986, 314:1129.
Grigoriadis, et al., Neuropsychopharmacology, 1989, 2:53.
Holsboer F. et al., Psychoneuroendocrinology, 1984, 9:147.
Koob G. F., Persp. Behav. Med., 1985, 2:39.
Morley, J.E. et al., Life Sci., 1987, 41:527.
Nakamura, H., Bull. Chem. Soc. Jpn., 1988, XP-00223312, vol. 61:3776.
Nemeroff, et al., Science, 1984, 226:1342.
Nemeroff C.B., et al., Arch. Gen Psychiatry, 1988, 45:577.
Rivier J. et al., Proc. Natl. Acad. Sci (USA), 1983, 80:4851.
Swerdlow, N. R., Psychopharmacology, 1986, 88:147-.
Vale W. et al, Science, 1981, 213:1394.
Vale W. et al, Rec. Prog. Horm. Res., 1983, 39:245.
Webster, E. L., J Rheumatol, Jun. 2002, 29(6):1252-61.
Zouboulis, C. C., Proc.Natl. Acad. Sci., 2001, 99, 7148-7153.
D. R. Britton, Intraventricular Corticotropin-Releasing Factor Enhances Behaviorial Effects of Novelty, Life Sciences, Vo. 3, 1982, pp. 363-367, Pergamon Press, U.S.A.
Corbett Jeffrey W.
Ennis Michael Dalton
Frank Kristine E.
Fu Jian-Min
Hoffman Robert Louis
Dorigo Andrea E.
Ling Lorrain B.
Pharmacia & Upjohn
Richardson Peter C.
Tucker Zachary C.
LandOfFree
Substituted pyrazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3519776